Better, Safer Prostate Biopsy™
“Like all cancers, screening is key and early detection makes a difference. PrecisionPoint® can provide better and earlier detection of prostate cancer, allowing patients to start treatment sooner and improve their outcomes.”
Dr. Matthew Allaway, Founder, Perineologic®
“Like all cancers, screening is key and early detection makes a difference. PrecisionPoint® can provide better and earlier detection of prostate cancer, allowing patients to start treatment sooner and improve their outcomes.”
Dr. Matthew Allaway, Founder, Perineologic®
Now there is a better option…
BENEFITS of OUR Approach
Improved Cancer Detection
No Bowel Prep
Speedy Recovery
Made In The USA
BENEFITS of OUR Approach
Improved Cancer Detection
No Bowel Prep
Speedy Recovery
Made In The USA
“I tell everyone I know who needs a biopsy: You don’t want the transrectal biopsy, you want the best that is available. With the PrecisionPoint®, my doctor was able to find the cancer.”
“I tell everyone I know who needs a biopsy: You don’t want the transrectal biopsy, you want the best that is available. With the PrecisionPoint®, my doctor was able to find the cancer.”
What Is PrecisionPoint®?
The PrecisionPoint® Transperineal Access System (PPTAS) is the first FDA cleared device allowing free-handed transperineal biopsy of the prostate. The device and technique eliminate the need for bowel prep and antibiotics prior to the prostate biopsy.
The procedure allows access to the prostate through the perineum or “taint”, avoiding the rectum completely. The procedure takes 15-20 minutes and can be performed under local or twilight anesthesia.
A recent study published in the British Journal of Urology found that 94% of missed cancers after transrectal prostate biopsies were located in the anterior region of the prostate. The PrecisionPoint® Transperineal Access System allows strategic sampling of the anterior portion of the prostate where these missed cancers have been found.
At Perineologic® , we understand your concern about the possibility of having prostate cancer. Your urologist is trained to perform a better, safer prostate biopsy using the PrecisionPoint® Transperineal Access System.
What Is PrecisionPoint®?
The PrecisionPoint® Transperineal Access System (PPTAS) is the first FDA cleared device allowing free-handed transperineal biopsy of the prostate. The device and technique eliminate the need for bowel prep and antibiotics prior to the prostate biopsy.
The procedure allows access to the prostate through the perineum or “taint”, avoiding the rectum completely. The procedure takes 15-20 minutes and can be performed under local or twilight anesthesia.
A recent study published in the British Journal of Urology found that 94% of missed cancers after transrectal prostate biopsies were located in the anterior region of the prostate. The PrecisionPoint® Transperineal Access System allows strategic sampling of the anterior portion of the prostate where these missed cancers have been found.
At Perineologic® , we understand your concern about the possibility of having prostate cancer. Your urologist is trained to perform a better, safer prostate biopsy using the PrecisionPoint® Transperineal Access System.
PrecisionPoint® is Revolutionizing Prostate Biopsy…
Due to its safety and effectiveness, this state-of-the-art approach is being rapidly adopted around the world.
PrecisionPoint® Procedures Performed Worldwide
Have a Question? Contact Us!
Thank you for your interest in Perineologic®!
Other Ways to Contact Us
(240) 727-7662
Perineologic®
183 N. Centre Street
Cumberland, MD 21502
United States
MEDIA CENTER : PrecisionPoint® and Related Topics
MEDIA CENTER : PrecisionPoint® and Related Topics
10
MAR2022STAT
News
In this STAT News article, medical journalist Howard Wolinsky discusses why active surveillance is an important option for men with low-risk prostate cancer...
24
FEB2022Medical
World News
Dr. Matthew Allaway provides an overview of the transperineal technique for prostate biopsy using PrecisionPoint™ in this installment of Inside the Practice...
21
FEB2022Med-Tech
Innovation
Check out this Q&A covering the transperineal approach to prostate biopsy with Dr. Matthew Allaway, founder and CEO, in Med-Tech Innovation...
14
FEB2022U.S.
FDA
We are pleased to see new guidance from FDA Device Info supports patient engagement to help improve clinical study design. ...
11
FEB2022Oncology
Peer Review
Dr. Allaway speaks with the Cancer Network about the important advances of the transperineal approach to prostate biopsy using PrecisionPoint™ ...
09
FEB2022Cancer Prevention
Foundation
February is National Cancer Prevention Month! We’re proud to join the prostate cancer advocacy community in putting a spotlight on the importance of early detection. Learn more...